Zosano Phar­ma CEO pass­es ba­ton down to suc­ces­sor; James Sapirstein takes the helm at Azur­Rx

→ Two years af­ter Zosano Phar­ma re­port­ed pos­i­tive Phase III da­ta for its mi­cronee­dle patch sys­tem for de­liv­er­ing an old mi­graine drug — set­ting up a cam­paign to file an NDA — the com­pa­ny has brought on Steven Lo to the helm as pres­i­dent and CEO. Lo will be suc­ceed­ing John Walk­er, who is re­tir­ing af­ter 48 years in the health­care in­dus­try. Walk­er will re­main as the chair­man of the board of di­rec­tors. Lo most re­cent­ly served as the CCO at Puma Biotech­nol­o­gy, where he helped with the launch of the com­pa­ny’s first prod­uct, Ner­l­ynx — whose Q1 sales fell un­com­fort­ably short of Wall Street es­ti­mates. In ad­di­tion, Lo was the CCO of Cor­cept Ther­a­peu­tics, where he led the es­tab­lish­ment of their first prod­uct, Ko­r­lym, a treat­ment for Cush­ing’s syn­drome. Ear­li­er in his ca­reer, Lo held stints at Genen­tech and As­traZeneca. Lo’s ap­point­ment comes a few weeks af­ter the com­pa­ny wel­comed Dushyant Pathak as SVP of busi­ness de­vel­op­ment. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER